Information Provided By:
Fly News Breaks for August 1, 2017
CLDX
Aug 1, 2017 | 07:04 EDT
H.C. Wainwright analyst Joseph Pantginis assumed coverage of Celldex Therapeutics with a Buy rating and $10 price target. The analyst expects an "important turnaround" over the next 12-months driven by the company's two lead assets, glembatumumab vedotin and varlilumab.
News For CLDX From the Last 2 Days
There are no results for your query CLDX